Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - powder for infusion - 2 g - active: ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - powder for injection - 0.5 g - active: ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - gargle - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat and mouth

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - oral spray - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33.06mg equivalent to cinacalcet 30 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66.12mg equivalent to cinacalcet 60 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99.18mg equivalent to cinacalcet 90 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear oy-29020 purified water sheffcoat green l tn 1264g49 starch - may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as an adjunctive therapy.